BML Capital Management, LLC
Sector Allocation
- Healthcare80.6%$141.1M
- Consumer Discretionary10.4%$18.2M
- Consumer Staples9.1%$15.9M
AUM History
13fpro.ai/research/fund/bml-capital-management-llc-1616824
Conviction and streaks
Stable · top 10 = 93.8%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
ACRS
$63.3MAVIR
$32.3MENGN
$11.5MKHC
$11.0MOM
$10.9MKMX
$9.1MTLYS
$9.0MPMVP
$7.1MTIL
$5.0MTGT
$4.9MORMP
$4.2MJANX
$2.4MPLRX
$1.8MCNTB
$1.4MIMA
$1.2M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/bml-capital-management-llc-1616824
BML Capital Management, LLC 13F holdings — Q2 2026
$176.1M portfolio (+13.0% QoQ) · 18 holdings · Q2 2026 13F · top 10 are 94% of the stock portfolio
Includes $954K of put/call options ($954K puts, $0 calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $175.1M. Weights use the stock portfolio.
$63.3M
36.2% of stocks
-16%This quarter-35.9%Since filed4+ qtrsHeld$32.3M
18.5% of stocks
-2%This quarter-20.8%Since filed4+ qtrsHeld$11.5M
6.6% of stocks
NewThis quarter-12.2%Since filedNew this quarterHeld$11.0M
6.3% of stocks
+272%This quarter-2.3%Since filed2 qtrsHeldAIQuality46.7#1,823Est. buyEstimated buy price is Pro: unlock with a free trialAdded 2 qtrs in a row$10.9M
6.2% of stocks
+32%This quarter-16.7%Since filed3 qtrsHeldAIQuality20.0#2,752Est. buyEstimated buy price is Pro: unlock with a free trialAdded 3 qtrs in a row$9.1M
5.2% of stocks
+11%This quarter-9.6%Since filed3 qtrsHeld$9.0M
5.2% of stocks
No changeThis quarter-0.2%Since filed2 qtrsHeld$7.1M
4.1% of stocks
+0.2%This quarter-5.0%Since filed4+ qtrsHeld$5.0M
2.8% of stocks
No changeThis quarter-24.8%Since filed4+ qtrsHeld$4.9M
2.8% of stocks
No changeThis quarter-0.8%Since filed4+ qtrsHeld
All holdings — BML Capital Management, LLC (Q2 2026)
18 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | ORAMED PHARMACEUTICALS INC. | Healthcare | $4.2M | 2.4% | 866K | -73% | 4+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | Janux Therapeutics, Inc. | Healthcare | $2.4M | 1.4% | 155K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | PLIANT THERAPEUTICS, INC. | Healthcare | $1.8M | 1.0% | 1.55M | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Connect Biopharma Holdings Ltd | Healthcare | $1.4M | 0.8% | 573K | +40% | 4+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | ImageneBio, Inc. | Healthcare | $1.2M | 0.7% | 201K | — | 4+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | Walmart Inc. | Consumer Staples | $386K | — | 335 | — | — | — | 13F | |
| 17 | Core Scientific, Inc./tx | Financials | $298K | — | 800 | New | — | — | 13F | |
| 18 | Tesla, Inc. | Consumer Discretionary | $270K | — | 375 | New | — | — | 13F |
What changed in Q2 2026
Against the previous quarter's 13F: 3 new, 5 added to, 3 trimmed, 1 sold out. Share-count changes; largest moves by dollar size first.
New positions (3)
Added to (5)
Trimmed (3)
Sold out (1)
$KZRKezar Life Sciences, Inc.was $5.3M
held 6+ qtrs
Holdings by quarter
Every 13F BML Capital Management, LLC has filed, 14 earlier quarters. Pick one to see what it held then.
Is it too late to follow BML Capital Management?
Q2 2026 13F filed with the SEC on Aug 7, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of BML Capital Management's top 20 holdings: 25/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)
Top 10 since filing
-21.6%
Value-weighted move of the 10 largest stock positions
Turnover
14%
Last quarter
Top 10 weight
94%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
68%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q3 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
BML Capital Management, LLC disclosed 18 positions worth $176.1M in its Form 13F-HR for Q2 2026 — $175.1M in common stock plus $954,088 of put/call option positions (reported at underlying notional value, not premium at risk), led by $ACRS (Aclaris Therapeutics, Inc.) at 36.2% of the equity portfolio, followed by $AVIR and $ENGN. During the quarter the fund opened 3 new positions and exited 1 — including a new stake in $ENGN and a full exit from $KZR. The portfolio is most concentrated in Healthcare (80.6% of disclosed assets). All figures are sourced directly from BML Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 1616824.
Funds like this
managers whose biggest positions overlap BML Capital Management'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: BML Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For BML Capital Management, LLC (SEC CIK: 1616824), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in BML Capital Management, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.